To offer comprehensive oncology laboratory testing and solutions
Cancer Genetics announced that it has entered into a partnership with the Laboratory Services group of ICON, the global CRO.
ICON’s Laboratory Services provide global testing services to the pharmaceutical, biotechnology and medical device industries. Reportedly, the partnership will provide clients access to combined expertise ranging from complex, oncology-focused genomic testing to core central laboratory analysis, project and data management and sample logistics on a global basis.
Together, the two companies will leverage their respective expertise to provide key insights to the oncology drug development and clinical trial process. The partnership is focused on providing a comprehensive, integrated and efficient solution for laboratory testing for global oncology trials from Phase I through Phase IV.
“We are looking forward to working with the CGI team and to enhancing our client offering with complementary laboratory service programs,” said James Miskel, Executive Vice President, ICON Laboratory Services. “Together, CGI and ICON are uniquely positioned to provide a full range of comprehensive lab solutions for our customers with current and future oncology-focused clinical trials.”
“This partnership will satisfy the enormous need among biotech and pharma companies for more efficient and comprehensive testing solutions by integrating CGI’s specialised, genomic testing to ICON’s laboratory solutions, “ said Panna Sharma, CEO of Cancer Genetics.”